Short answer
CVRx, Inc. (CVRX) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Chief Revenue Officer Robert John departed CVRx effective August 10, 2026.
CVRx, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Chief Revenue Officer Robert John departed CVRx effective August 10, 2026
- Termination triggers severance pay and benefits under his employment agreement, subject to contractual conditions
- Immediate CRO vacancy creates potential near-term sales execution and leadership-transition risk
Item EX-99.1 · Exhibit EX-99.1
- Chief Revenue Officer Robert John departing; Paul Verrasto appointed Interim Head of Sales effective immediately
- Leadership change driven by revised commercial outlook and need to improve commercial execution
- Interim leader brings more than 30 years of medical device sales and marketing experience
- Permanent sales leadership search underway, creating near-term execution and transition risk
- Barostim remains CVRx’s FDA-approved heart-failure therapy and core commercial product
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CVRx, Inc. 8-K filings
Get the next CVRX 8-K as it lands
Follow CVRX for push alerts, or ask the research agent what this filing means.